

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Takaki Koga et al.
Serial No. : 10/542,682
Filed : December 14, 2005

Art Unit : 1645
Examiner : Unknown
Conf. No. : 5413

Title : ANTI-PCI NEUTRALIZING ANTIBODIES

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form.

This statement is being filed before the receipt of a first Office Action on the merits.

No fee is believed due. Please apply any charges to deposit account 06-1050, referencing attorney docket 14875-147US1.

Respectfully submitted,

Date: _____

6-20-2006



Jianming Hao
Reg. No. 54,694

Customer No. 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-147US1	Application No. 10/542,682
		Applicant Takaki Koga et al.	
		Filing Date December 14, 2005	Group Art Unit 1645
Information Disclosure Statement by Applicant (Use several sheets if necessary)			
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AA	1 222 929	7/17/2002	EP				
	AB	11-124399	5/11/1999	JP (with English Abstract)				
	AC	00-47626	8/17/2000	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AD	Cooper et al. "Intermolecular interactions between protein C inhibitor and coagulation proteases". <i>Biochemistry</i> 34:12991-12997, 1995.
	AE	Elisen et al. "Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma". <i>Blood</i> 91(5):1542-1547, 1998.
	AF	Meijers et al. "Identification of monoclonal antibodies that inhibit the function of protein C inhibitor. Evidence for heparin-independent inhibition of activated protein C in plasma". <i>Blood</i> 74(2):1401-1403, 1988.
	AG	Strandberg et al. "A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes". <i>Blood Coagulation and Fibrinolysis</i> 12(7):503-510, 2001.
	AH	Strandberg et al. "Complexes between activated protein C and protein C inhibitor measured with a new method". <i>Thromb Haemost</i> 86:1400-1408, 2001.
	AI	Suzuki. "Protein C inhibitor (PAI-3): structure and multi-function". <i>Fibrinolysis & Proteolysis</i> 14(273):133-145, 2000.
	AJ	Suzuki et al. "Mechanism of inhibition of activated protein C by protein C inhibitor". <i>J. Biochem</i> 95:187-195, 1984.
	AK	Suzuki et al. "Protein C inhibitor". <i>Journal of Biological Chemistry</i> 258(1):163-168, 1983.
	AL	Suzuki et al. "Characterization of a cDNA for human protein C inhibitor". <i>Journal of Biological Chemistry</i> 262(2):611-616, 1987.
	AM	Taylor et al. "Protein C prevents the coagulopathic and lethal effects of <i>Escherichia coli</i> infusion in the baboon". <i>J. Clin. Invest.</i> 79:918-925, 1987.
	AN	Taylor et al. "DEGR-Factor Xa blocks disseminated intravascular coagulation initiated by <i>Escherichia coli</i> without preventing shock or organ damage". <i>Blood</i> 78(2):364-368, 1991.
	AO	Watanabe et al. "Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states". <i>American Journal of Hematology</i> 65:35-40, 2000.
	AP	Ware et al. "Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 363 of factor VIII heavy chain". <i>Proc. Natl. Acad. Sci. USA</i> 85(9):3165-3169, May 1988.
	AQ	
	AR	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	